Abstract Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers; however, durable response is limited to only a subset of patients. Discovery blood-based biomarkers that reflect dynamic change the tumor microenvironment, and predict ICI, will markedly improve current regimens. Here, we investigate CX3C chemokine receptor 1 (CX3CR1), marker T-cell differentiation, a...

Pheochromocytomas (PCCs) are rare neuroendocrine tumors. The current diagnostic tools are based on biochemistry and histopathology results, but heterogeneity of diagnostic markers, signs and symptoms of PCCs bring a lot of difficulties for these two current methods. Unfortunately microscopic understanding of PCCs is not adequate for its confident prognosis and management. There are data linking...

Metastatic cancer can recur months or even years after apparently successful treatment of the primary tumor. While the exact mechanisms leading to cancer recurrence remain poorly understood, failure to completely eliminate dormant micrometastases and solitary metastatic cells is believed to be a major contributor. Thus, while not of initial clinical concern, metastatic dormancy is still a signi...